TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7833219
Drug: L-NG-monomethyl-arginine (L-NMMA)
Normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NG-monomethyl-arginine (L-NMMA) 4 mumol min-1 for 5 min
Study: 7833219
Drug: Bradykinin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin 10 and 100 pmol min-1 for 3 min each dose
Study: 7833219
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) 2 and 5 nmol min-1 for 3 min each dose
Study: 19628666
Drug: Bradykinin B(2)
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin B(2) receptor blocker HOE‐140
Study: 8845473
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 100 mg/m2/day for 5 days
Study: 8845473
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 75 mg/m2/day for 5 days
Study: 8845473
Drug: Etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide phosphate (EP) at 50 or 75 mg/m2/day for 5 days
Study: 25850865
Drug: Tight glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glycemic control with insulin (insulin titrated to maintain blood glucose between 80 and 110 mg/dL)
Study: 22192068
Drug: myo-inositol 2
Normalized name: myo-Inositol 2-dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: myo-inositol 2 g b.i.d. (n = 40)
Study: 22192068
Drug: myo-inositol 2
Normalized name: myo-Inositol 2-dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: myo-inositol 2 g b.i.d.
Study: 15660059
Drug: Intravenous, intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, intraoperative unfractionated heparin
Study: 15660059
Drug: Intravenous, intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, intraoperative saline (Control)
Study: 11877611
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (dalteparin: 2,500 IU for ≤70 kg and 5,000 IU for >70 kg, started perioperatively and given once daily for 4 weeks)
Study: 8701511
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 mcg (b.i.d.)
Study: 8701511
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol controlled release 8 mg (b.i.d.)
Study: 18709511
Drug: Esomeprazole (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20-40 mg daily)
Study: 25692384
Drug: Topical rapamycin
Normalized name: natamycin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin gel, 0.2%, applied twice a day for 12 weeks
Study: 25692384
Drug: Topical rapamycin
Normalized name: natamycin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rapamycin treatment
Study: 23434908
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (12 mg of lutein and 280 mg of DHA daily)
Study: 19681943
Drug: TiO(2) thin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiO(2) thin film modified implants
Study: 16696748
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including occupational and physical therapy sessions, home modifications, problem-solving strategies, energy conservation, safe performance techniques, fall recovery techniques, balance and muscle strength training.
Study: 1564023
Drug: Sustained-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release methylphenidate (MPH)
Study: 1564023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of standard and sustained-release MPH
Study: 29544062
Drug: CHO drink
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO drink (75 g CHO)
Study: 29544062
Drug: CHO+PRO drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+PRO drink (60.5 g CHO and 14.5 g PRO)
Study: 22571514
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control with release time
Study: 22571514
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control with routine duties
Study: 18953465
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of saccharides
Study: 11379469
Drug: Modified short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified short-course chemotherapy (S: streptomycin, H: isoniazid, R: Rifampicin, Z: pyrazinamide) for 2 months followed by 6 months of thiacetazone and isoniazid (2SHRZ/6TH or 2EHRZ/6TH)
Study: 2899509
Drug: xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 200 mg twice daily
Study: 1675867
Drug: enalapril 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 2.5, 5 or 10 mg twice daily
Study: 1675867
Drug: xamoteril 200
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoteril 200 mg twice daily
Study: 24750799
Drug: Guna‐Interleukin 4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guna‐Interleukin 4, Guna‐Interleukin 10, and Guna‐Interleukin 11 at the concentration of 10 fg/ml
Study: 12917745
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements for 12 months
Study: 12917745
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nutritional supplements)
Study: 10919170
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (30 g alcohol/day)
Study: 10919170
Drug: Alcoholic solution
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic solution (same degree of alcohol)
Study: 8737133
Drug: Sparfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily)
Study: 8737133
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg orally twice daily for 10 to 14 days)
Study: 1570375
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptylinoxide (AT‐NO) IV
Study: 1570375
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptylinoxide (AT‐NO) orally
Study: 1570375
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptyline (AT) IV
Study: 1570375
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with AT‐NO
Study: 1570375
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with AT
Study: 16210665
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d of fish oil
Study: 16210665
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d of soy oil
Study: 12358655
Drug: Ondansetron 0.1
Normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.1 mg x kg(‐1)
Study: 12358655
Drug: Droperidol 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.01 mg.kg‐1
Study: 1557928
Drug: Monocomponent pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocomponent pertussis toxoid vaccine
Study: 9690722
Drug: famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 10 mg
Study: 7590425
Drug: cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 200 mg
Study: 7590425
Drug: cimetidine 100
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 100 mg
Study: 6893378
Drug: Cimetidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (0.3 mg/kg i.v. bolus)
Study: 6893378
Drug: Secretin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secretin (3 CU/kg/h i.v. infusion)
Study: 6137116
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cimetidine and pirenzepine
Study: 29105631
Drug: Cosmetic cream
Normalized name: POLYGONUM CUSPIDATUM LEAF 0.05 g in 50 g / CENTELLA ASIATICA LEAF 0.05 g in 50 g / RETINOL 0.05 g in 50 g / CERAMIDE NP 0.05 g in 50 g / ROSMARINUS OFFICINALIS FLOWER 0.05 g in 50 g TOPICAL CREAM [BARUBT A313 Cosmetic Cream With Retinyl Palmitate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic cream containing 4% Saussurea lappa extract
Study: 19948613
Drug: Oral 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 25% dextrose treatment, given 2 minutes before the injection
Study: 19948613
Drug: Skin-to-skin contact,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin-to-skin contact, initiated 2 minutes before the injection and persisting throughout the procedure
Study: 19948613
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral 25% dextrose treatment and skin-to-skin contact
Study: 15035552
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of oocyte retrieval (Group A)
Study: 15035552
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of embryo transfer (Group B)
Study: 2783702
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 40 mg/day)
Study: 9569795
Drug: Piroxicam FDDF
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam FDDF 40 mg
Study: 8371917
Drug: PhXA41 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (35 micrograms/ml)
Study: 8371917
Drug: PhXA41 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (60 micrograms/ml)
Study: 8371917
Drug: PhXA41 (115
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (115 micrograms/ml)
Study: 3524514
Drug: RS-86 (muscarinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RS-86 (muscarinic agonist) administered orally at maximum individually tolerated dose levels for eight days
Study: 29505772
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg every 6 hours
Study: 29505772
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg every 6 hours
Study: 24420746
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg/day
Study: 24420746
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg with rifampin 600 mg/day
Study: 20934562
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone replacement therapy (non-HRT)
Study: 15199033
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser treatment (fluence of 3 J/cm2)
Study: 9012902
Drug: Helium/oxygen (He/O2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helium/oxygen (He/O2) inhalation for 90 minutes
Study: 28663621
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (0.3 mg)
Study: 26557673
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with antioxidants/omega 3 fatty acids (A/ω3) for three months
Study: 23301559
Drug: Benzocaine mucoadhesive
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzocaine mucoadhesive patches (20%)
Study: 18450232
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of ondansetron intravenously 30 minutes prior to completion of the surgery
Study: 18450232
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of ondansetron intravenously prior to the induction of anesthesia
Study: 17557432
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of pseudoephedrine sulfate and 10 mg of domperidone at bedtime for 30 days (open-label trial)
Study: 17557432
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Study: 17557432
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Study: 17557432
Drug: Drug combination
Normalized name: Other anti-dementia drug combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combination (pseudoephedrine sulfate and domperidone)
Study: 15058039
Drug: antibiotics only
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotics only
Study: 10716106
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment (77 patients)
Study: 10716106
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment (65 patients)
Study: 9360163
Drug: WBHT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBHT in patients on protease inhibitor/triple drug therapy
Study: 1550466
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg/d and 20 mg/d
Study: 3898350
Drug: Cimetidine maintenance
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine maintenance therapy
Study: 27528611
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL hyaluronic acid (HA) injection at the end of arthroscopic meniscectomy
Study: 23924070
Drug: KOH 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH 10% solution applied two times a day until lesions disappeared
Study: 23924070
Drug: Cryotherapy performed
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy performed with liquid nitrogen spray, repeated weekly for 4 weeks
Study: 20196969
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g of n-3 polyunsaturated fatty acids (n-3 PUFA) daily for 24 weeks
Study: 15242867
Drug: Algorithm guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm guided by oesophageal Doppler flowmetry to maintain a stroke index above 35 ml/m2
Study: 9676822
Drug: m-CPP (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (0.08 mg/kg i.v.) + placebo
Study: 9676822
Drug: m-CPP (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-CPP (0.08 mg/kg i.v.) + ondansetron (0.15 mg/kg i.v.)
Study: 9676822
Drug: ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (0.15 mg/kg i.v.) + placebo
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 40 mg/min
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 60 mg/min
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 75 mg/min
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 150 mg/min
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 300 mg/min
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 600 mg/min
Study: 8053580
Drug: Thiopental infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental infusion rate of 1200 mg/min
Study: 7431552
Drug: Erythromycin ophthalmic
Normalized name: erythromycin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin ophthalmic ointment
Study: 2922026
Drug: Tetracycline ophthalmic
Normalized name: oxytetracycline ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline ophthalmic ointment
Study: 27434297
Drug: Nilotinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (both doses)
Study: 27997805
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Cannula (HFNC) set at 40 L/min
Study: 21154013
Drug: 30MIN (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30MIN (75 g isomaltulose, 75% reduced insulin dose)
Study: 7499109
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate 22.5 mg/m2 every 6 hours
Study: 7499109
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate 30 mg/m2 every 6 hours
Study: 7499109
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate (various doses)
Study: 1775522
Drug: Minaprine 200
Normalized name: minaprine
DrugBank: Minaprine (DB00805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 200 mg per day
Study: 1775522
Drug: Minaprine 300
Normalized name: minaprine
DrugBank: Minaprine (DB00805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 300 mg per day
Study: 9133750
Drug: Imipramine 150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 150 mg per day
Study: 27830357
Drug: Ulinastatin (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (10,000 U/kg before anesthesia and 5000 U/kg daily on postoperative days 1 to 3)
Study: 19694636
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 mg, n = 74)
Study: 19694636
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg, n = 69)
Study: 17445350
Drug: Arachidonate-enriched TAG
Normalized name: arachidonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arachidonate-enriched TAG supplementation (838 mg ARA/d for 2 weeks)
Study: 17445350
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (dietary intakes of arachidonic acid 179 (se13) mg/d)
Study: 15451546
Drug: Deramciclane 30
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 30 mg tablet administered after a high-fat meal
Study: 15451546
Drug: Deramciclane 30
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 30 mg tablet administered after an overnight fast
Study: 30072135
Drug: PACRR scale
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACRR scale (19-item scale) administered to physicians
Study: 25641045
Drug: Olopatadine, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine, a second-generation antihistamine
Study: 24228847
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day vitamin C for 3 months (group 1)
Study: 24228847
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day vitamin C for 3 months (group 2)
Study: 21864352
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment with a sling
Study: 16319603
Drug: Aggressive acid-suppressive
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive acid-suppressive therapy for 4 months
Study: 8929247
Drug: Myrin tablets
Normalized name: Bio-Mycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrin tablets (300 mg rifampicin, 150 mg isoniazid, 600 mg ethambutol HCl)
Study: 8929247
Drug: Reference (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (300 mg rifampicin, 200 mg isoniazid, 600 mg ethambutol HCl)
Study: 1964020
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (31.7 g per day for 6 months)
Study: 1964020
Drug: Soluble gums
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble gums (average of 19.5 g of added fiber per day for 4 weeks)
Study: 23159524
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg BUP
Study: 23159524
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg BUP
Study: 21531237
Drug: Tailored behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored behavioral self-management intervention administered via telephone by a nurse every other month
Study: 21531237
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of home blood pressure monitoring and tailored behavioral self-management intervention
Study: 19704064
Drug: Six courses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six courses of paclitaxel 175 mg/m² every 3 weeks (maintenance)
Study: 11758844
Drug: Gentamicin 2.0-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2.0-2.5 mg/kg twice daily
Study: 11758844
Drug: Gentamicin 4.0-5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4.0-5.0 mg/kg once daily